Jefferies says Onyx Pharmaceutical (ONXX +6.3%) is positioned for a strong Kyprolls launch ....

|By:, SA News Editor

Jefferies says Onyx Pharmaceutical (ONXX +6.3%) is positioned for a strong Kyprolls launch . After conducting a survey, the firm says the drug's impact is deeply undervalued by the Street and may significantly surpass estimates, which it turn will benefit its share price. It reiterates a Buy rating and maintains a $101 target on the stock.